Valuation positioning and trading range stability align with broader nasdaq index sentiment. NeoGenomics, Inc. (NASDAQ:NEO) ...

NeoGenomics’ fourth quarter results were met with a negative market reaction, despite revenue and non-GAAP earnings per share surpassing Wall Street’s expectations. Management attributed the quarter’s ...

What Happened? Shares of oncology (cancer) diagnostics company NeoGenomics (NASDAQ:NEO) fell 10.1% in the afternoon session ...

NeoGenomics (NASDAQ:NEO) strengthens its position in Nasdaq today with strong institutional backing and growth in ...

Cancer-testing company NeoGenomics (NASDAQ:NEO) is in the midst of a brutal pullback today after announcing it will miss guidance. NEO stock is down more than 30% so far on Tuesday. So what is going ...

Today, we take our first look at NeoGenomics, Inc., a company focused on oncology testing. NeoGenomics has strung together a series of strong quarterly results that has helped the shares double so far ...

NeoGenomics NEO has been analyzed by 4 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish. The table below offers a condensed view of their recent ...

NeoGenomics (NEO) has been on a downward spiral lately with significant selling pressure. After declining 22.8% over the past ...

NeoGenomics (NEO) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #1 (Strong Buy). This upgrade is essentially a reflection of an upward trend in earnings ...

NeoGenomics (NEO) could be a solid choice for investors given its recent upgrade to a Zacks Rank #1 (Strong Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- ...

Event context and recent share performance NeoGenomics (NEO) has been on many investors’ radars after a tough stretch in the share price, with negative returns over the past week, month and past 3 ...